This is an open-label phase 1 study to assess the safety and pharmacodynamics of CART-BCMA, with or without huCART19, in patients responding to first- or second-line therapy for high-risk multiple myeloma.
The regimen evaluated in this study is based on established safety of CARTBCMA demonstrated in UPCC 14415/IRB#822756 at dose of 5x108 cells, administered as split infusions, following cyclophosphamide 1.5 g/m2 in patients with relapsed/refractory myeloma.
This study tests CART-BCMA:
Cyclophosphamide is a chemotherapy cancer medication that interferes with the growth and spread of cancer cells in the body. It can be given as a pill, a liquid, or as an injection into a vein through an IV.
The following criteria is provided for health care professionals.
Call us at (888) 828-2206 and we can answer any questions and help get you connected with this study team.
Our system will analyze your profile against hundreds of clinical trials to find ones that may be right for you.
This center is currently accepting patients.
This trial is currently open and accepting patients.
39 sparks required
Weekdays 9am - 5pm EST
Create your account today and we can alert you when this trial opens recruitment.
Or call us today, and we can help answer any questions that you may have.